一项多中心研究,研究了儿科急性淋巴细胞白血病中普得尼松反应的预后价值
Jia-Tong Dai1, Yun-Yan He2, Ya-Ting Zhang3
1Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Annals of hematology
|October 10, 2025
概括
儿科急性淋巴细胞白血病 (ALL) 中的普雷尼松反应 (PR) 与早期最小残留疾病 (MRD) 有关,但不是一个独立的预后因素. 在资源有限的环境中,PR可以作为MRD的替代品.
科学领域:
- 儿科瘤学 儿科瘤学
- 血液学 血液学 血液学
- 临床研究 临床研究
背景情况:
- 普雷尼松反应 (PR) 是儿科急性淋巴细胞白血病 (ALL) 的关键早期指标.
- 它的独立预后价值随着最小残留疾病 (MRD) 评估的增加而下降.
- 了解PR的作用,特别是在高风险ALL中,对于完善治疗至关重要.
研究的目的:
- 评估儿科急性淋巴细胞白血病 (ALL) 预尼松反应 (PR) 的临床和生物意义.
- 评估PR与早期最小残留疾病 (MRD) 在一个大队列中的关联.
- 在MRD引导治疗时代确定PR的独立预后价值.
主要方法:
- 来自SCCLG-ALL-2016协作小组的2,979名儿科ALL患者的回顾性分析.
- 分类为良好的普得尼松反应 (GPR) 和不良的普得尼松反应 (PPR) 组.
- 逻辑回归用于PR-MRD相关性和Cox回归用于预后因素分析.
主要成果:
- 总共有2,649名患者是GPR,330人是PPR.
- PPR患者有更多的高风险特征和更差的预后.
- 15日和33日MRD水平是比PR更强的预测指标,尽管PR强烈预测了MRD阳性.
结论:
- 普雷尼松反应不是这个中国ALL队列的独立预后标志物,但与早期MRD有很强的关联.
- 在资源有限的环境中,PR可以成为MRD的实际替代品.
- 在现代风险适应的ALL治疗策略中PR的作用需要重新考虑.
关键词:
急性淋巴细胞白血病 (Acute Lymphoblastic Leukemia) 是一种急性淋巴细胞白血病.最少残留疾病的最小残留疾病.儿科研究中的儿科研究预尼松的反应反应预测 预后 预测 预测更多相关视频
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.6K
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
565
相关概念视频
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...